Balsan S, Garabedian M, Liberman U A, Eil C, Bourdeau A, Guillozo H, Grimberg R, Le Deunff M J, Lieberherr M, Guimbaud P, Broyer M, Marx S J
J Clin Endocrinol Metab. 1983 Oct;57(4):803-11. doi: 10.1210/jcem-57-4-803.
Two unrelated patients, aged 22 months and 31 months, with alopecia and rickets resistant to 1,25-dihydroxyvitamin D (1,25-(OH)2D] (vitamin D-dependency type II) presented with similar biochemical and radiologic features. They were treated with large doses of vitamin D3 derivatives [25-hydroxyvitamin D3 (25-(OH)D3), 1,25-(OH)2D3, and 1 alpha-hydroxyvitamin D3] for 28 months and 6 yr, respectively. In both patients, serum 1,25-(OH)2D levels remained high (approximately 10- to 100-fold normal) during the different therapeutic regimens. Circulating 1,25-(OH)2D and 24,25-dihydroxyvitamin D levels at various stages of the disease suggested in these children disturbances in the regulation of 25-hydroxyvitamin D (25(OH)D) 1 alpha- and 24-hydroxylase systems. In one child, all therapeutic trials were unsuccessful. Studies of her cultured skin fibroblasts showed low capacity (10% normal) for saturable (presumably receptor mediated) nuclear uptake of tritiated 1,25-(OH)2D3; the uptake process of nucleus associated 1,25-(OH)2D3 was normal in apparent affinity for 1,25-(OH)2D3 and in sedimentation velocity of nucleus-associated hormone. In the second child, correction of biochemical abnormalities, healing of rickets, and catch-up growth were obtained during similar therapeutic trials up to the age of 6 yr when a relapse occurred. This relapse has persisted for 2 yr in spite of similar or higher circulating concentrations of 25-(OH)D and 1,25-(OH)2D than those obtained previously when she was responsive to therapy. In her cultured skin fibroblasts, saturable high affinity nuclear uptake of 1,25(OH)2D was unmeasurable.
两名年龄分别为22个月和31个月的无关患儿,患有对1,25 - 二羟维生素D(1,25-(OH)₂D)抵抗的脱发和佝偻病(II型维生素D依赖性),表现出相似的生化和放射学特征。他们分别接受大剂量维生素D₃衍生物[25 - 羟维生素D₃(25-(OH)D₃)、1,25-(OH)₂D₃和1α - 羟维生素D₃]治疗28个月和6年。在两名患儿中,在不同治疗方案期间血清1,25-(OH)₂D水平均保持较高(约为正常水平的10至100倍)。疾病不同阶段循环中的1,25-(OH)₂D和24,25 - 二羟维生素D水平提示这些儿童25 - 羟维生素D(25(OH)D)1α - 羟化酶和24 - 羟化酶系统的调节存在紊乱。在一名患儿中,所有治疗试验均未成功。对其培养的皮肤成纤维细胞研究显示,氚标记的1,25-(OH)₂D₃可饱和(推测为受体介导)核摄取能力较低(为正常水平的10%);细胞核相关的1,25-(OH)₂D₃摄取过程在对1,25-(OH)₂D₃的表观亲和力和细胞核相关激素的沉降速度方面是正常的。在第二名患儿中,在类似治疗试验期间,直至6岁复发前,生化异常得到纠正,佝偻病愈合且出现追赶生长。尽管循环中的25-(OH)D和1,25-(OH)₂D浓度与之前对治疗有反应时相似或更高,但这次复发仍持续了2年。在她培养的皮肤成纤维细胞中,无法检测到1,25(OH)₂D的可饱和高亲和力核摄取。
1)II型维生素D依赖性综合征患者可出现不同的临床反应模式,且可能与1,25-(OH)₂D₃与培养的皮肤成纤维细胞相互作用的不同异常有关;2)在一些患者的长期治疗过程中,对1,25-(OH)₂D₃的抵抗可能会加重。